Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 134
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03948763 | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | ||
| NCT04975893 | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | ||
| NCT05375838 | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old | ||
| NCT07266558 | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | ||
| NCT05440318 | Use of Wearable Digital Sensors After mRNA Vaccination in Adults | ||
| NCT04916431 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults | ||
| NCT05575492 | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | ||
| NCT06354998 | A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults | ||
| NCT04813796 | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 | ||
| NCT04283461 | Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) | ||
| NCT05894525 | Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine | ||
| NCT06077760 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | ||
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | ||
| NCT06143046 | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers | ||
| NCT05831111 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | ||
| NCT04232280 | Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults | ||
| NCT03810690 | Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia | ||
| NCT03313778 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors | ||
| NCT05918250 | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | ||
| NCT04528719 | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | ||
| NCT05659264 | A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure | ||
| NCT06113692 | A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine | ||
| NCT04958304 | Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study | ||
| NCT06585241 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | ||
| NCT06033261 | A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes | ||
| NCT04860297 | A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants | ||
| NCT06508320 | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | ||
| NCT05130437 | A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study | ||
| NCT06522880 | Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study | ||
| NCT06602024 | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age | ||
| NCT05868382 | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults | ||
| NCT04405076 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | ||
| NCT04956575 | A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults | ||
| NCT05933577 | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | ||
| NCT05972174 | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | ||
| NCT06864143 | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age | ||
| NCT05295433 | An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 | ||
| NCT05398796 | Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults | ||
| NCT03484767 | "The MaP Study": Mapping the Patient Journey in MMA and PA | ||
| NCT05794412 | Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study | ||
| NCT05894590 | Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19 | ||
| NCT05333289 | A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults | ||
| NCT06694389 | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age | ||
| NCT03829384 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults | ||
| NCT06333704 | Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection. | ||
| NCT05280158 | High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients | ||
| NCT03076385 | Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects | ||
| NCT05001373 | A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) | ||
| NCT06130345 | Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran | ||
| NCT05933304 | A Study of the Effectiveness of Moderna COVID-19 Vaccine |
